Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients

SIMPLE SUMMARY: Patients whose breast cancers express low levels of hormone receptor (HR) could be eligible for adjuvant endocrine therapy; however, limited data are available to support this notion. Our retrospective study investigated the characteristics and survival of 6042 breast cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Jee Hyun, Choi, Soon Bo, Park, Jung Min, Kim, Jee Ye, Park, Hyung Seok, Kim, Seung Il, Park, Byeong-Woo, Park, Seho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508141/
https://www.ncbi.nlm.nih.gov/pubmed/34638491
http://dx.doi.org/10.3390/cancers13195007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508141/
https://www.ncbi.nlm.nih.gov/pubmed/34638491
http://dx.doi.org/10.3390/cancers13195007

Ejemplares similares